Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit

Restricted access

Dr. Kato is an Assistant Professor of Medicine at University of California, San Diego. He treats a wide variety of cancers, including gastrointestinal cancer and rare tumors. His research focus is investigating the novel targeted therapy approach as well as understanding the resistant mechanism from targeted agents.The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.Dr. Subbiah, a clinical trials investigator, is currently an Assistant Professor in the Department of Investigational Cancer Therapeutics (A Phase 1 Program), Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center. Dr. Subbiah has a unique training background in that he is one of the few physicians in the nation to have training in oncology in both adults and children. He is primarily involved in translational cancer research and the design/conduct of early-phase, biomarker-driven clinical trials, with a special interest in precision oncology and immunoconjugate trials. He is a major advocate for precision oncology and personalized medicine.Dr. Subbiah receives research funding for clinical trials from Roche/Genentech, Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, and Bluprint Medicines.Dr. Kurzrock is a Senior Deputy Director, UCSD Moores Cancer Center; Director, Center for Personalized Cancer Therapy and Clinical Trial Office; and Chief, Division of Hematology and Oncology at University of California, San Diego. She developed the largest phase I clinical trials department in the world at The University of Texas MD Anderson Cancer Center before being appointed at University of California, San Diego. At the Center for Personalized Cancer Therapy, she uses advanced molecular technologies to match patients with cancer with genomically targeted therapies and immunotherapy to optimize the chance for response.She receives consultant fees from X-biotech and from Actuate Therapeutics, as well as research funds from Genentech, Pfizer, Sequenom, Guardant, Foundation Medicine, and Merck Serono, and has an ownership interest in CureMatch Inc.
  • 1.

    Le TourneauCDelordJPGoncalvesA. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol2015;16:13241334.

    • Search Google Scholar
    • Export Citation
  • 2.

    GarayJPGrayJW. Omics and therapy - a basis for precision medicine. Mol Oncol2012;6:128139.

  • 3.

    SchwaederleMZhaoMLeeJJ. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol2016;2:14521459.

    • Search Google Scholar
    • Export Citation
  • 4.

    HymanDMPuzanovISubbiahV. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med2015;373:726736.

  • 5.

    WhelerJJJankuFNaingA. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res2016;76:36903701.

    • Search Google Scholar
    • Export Citation
  • 6.

    JardimDLSchwaederleMWeiC. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst2015;107. pii: djv253.

    • Search Google Scholar
    • Export Citation
  • 7.

    SchwaederleMZhaoMLeeJJ. Impact of precision medicine indiverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol2015;33:38173325.

    • Search Google Scholar
    • Export Citation
  • 8.

    PatelSPKurzrockR. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther2015;14:847856.

  • 9.

    SubbiahVKurzrockR. Universal genomic testing needed to win the war against cancer: genomics IS the diagnosis. JAMA Oncol2016;2:719720.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 289 230 15
PDF Downloads 68 65 2
EPUB Downloads 0 0 0